商业保险人群中晚期基底细胞癌的疾病负担与治疗模式(2010-2014)
本研究基于美国商业保险理赔数据库,回顾性分析2010至2014年间847对匹配的晚期基底细胞癌(aBCC)与非aBCC患者。结果显示aBCC患者合并症指数更高,门诊、皮肤科及肿瘤科就诊次数更多,总医疗费用及BCC治疗费用显著更高,费用差异主要由放疗驱动。
要点
- aBCC患者较非aBCC患者有更高的疾病负担和医疗资源使用。
- aBCC患者的总医疗费用及BCC治疗费用显著更高,差异主要由放疗费用驱动。
- 该研究基于商业保险理赔数据,算法可能限制患者数量,且未完全反映靶向治疗时代。
核心结论
- 晚期基底细胞癌患者比非晚期患者具有更高的疾病负担,费用差异主要由BCC治疗费用特别是放疗驱动。
研究设计与样本
- 回顾性、基于保险理赔的研究设计,纳入≥2次BCC诊断相关理赔(间隔≥30天)的成人患者,按算法分类为aBCC或非aBCC,并按年龄、性别和地区1:1匹配,共847对匹配患者(平均年龄75岁,57%男性;局部晚期826例,转移性21例)。
临床怎么用
- 临床应关注晚期基底细胞癌患者较高的合并症负担及多学科就诊需求。
- 在晚期基底细胞癌管理中,应重视放疗相关费用对总体医疗费用的影响。
局限性
- 研究仅包含商业保险和 Medicare 理赔数据库信息。
- 算法标准可能限制了患者数量。
- 数据未完全反映靶向治疗时代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The burden of advanced basal cell carcinoma (aBCC) is not fully understood. OBJECTIVE: To compare BCC disease burden and treatment patterns for aBCC with those for non-aBCC. METHODS: A retrospective, insurance claims-based study design was used. Adults with ≥2 claims associated with a BCC diagnosis (ICD-9-CM 173.x1) separated by ≥30 days on or after October 1, 2011, were classified as aBCC or non-aBCC by using an algorithm based on metastasis diagnosis, radiation therapy use, and medical oncologist/other specialist use. Non-aBCC and aBCC patients were matched 1:1 on the basis of age, sex, and region, and assigned the same index date (date of first qualifying diagnosis or event). Comparisons were made using Wilcoxon signed-rank (continuous variables) and McNemar's (categorical variables) tests. RESULTS: In total, 847 matched aBCC/non-aBCC patient pairs were selected (mean age 75 years; 57% men; locally advanced BCC, n = 826; metastatic BCC, n = 21). During the 12-month study period following the index date, aBCC patients had a significantly higher mean Charlson Comorbidity Index (P = .0023), significantly higher mean numbers of outpatient/dermatologist/medical oncologist visits (all P < .0001), and significantly higher mean total/medical/inpatient/outpatient/BCC treatment costs (all P < .05). LIMITATIONS: This study only included information from a database on commercial insurance and Medicare claims. The algorithm criteria might have restricted patient numbers; data were not fully reflective of targeted therapy era. CONCLUSIONS: aBCC patients had a higher disease burden than non-aBCC patients. Cost differences were largely driven by higher BCC treatment costs, specifically radiation therapy.
引用
- Migden M, Xie J, Wei J, et al. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol. 2017. PMID: 28392293. doi:10.1016/j.jaad.2017.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。